Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to $25.8 million.

  • Kyntra Bio's Accumulated Expenses fell 8294.57% to $25.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.8 million, marking a year-over-year decrease of 8294.57%. This contributed to the annual value of $62.0 million for FY2024, which is 5335.26% down from last year.
  • According to the latest figures from Q3 2025, Kyntra Bio's Accumulated Expenses is $25.8 million, which was down 8294.57% from $35.9 million recorded in Q2 2025.
  • Kyntra Bio's 5-year Accumulated Expenses high stood at $219.8 million for Q4 2022, and its period low was $25.8 million during Q3 2025.
  • Moreover, its 5-year median value for Accumulated Expenses was $151.3 million (2021), whereas its average is $138.6 million.
  • As far as peak fluctuations go, Kyntra Bio's Accumulated Expenses surged by 19288.4% in 2021, and later crashed by 8294.57% in 2025.
  • Quarter analysis of 5 years shows Kyntra Bio's Accumulated Expenses stood at $172.6 million in 2021, then grew by 27.33% to $219.8 million in 2022, then plummeted by 39.49% to $133.0 million in 2023, then plummeted by 53.35% to $62.0 million in 2024, then tumbled by 58.45% to $25.8 million in 2025.
  • Its Accumulated Expenses was $25.8 million in Q3 2025, compared to $35.9 million in Q2 2025 and $35.3 million in Q1 2025.